SpinCeutica, Inc.

Biotech · Private

Deuterated ambroxol and isotope-labeled INH combination therapy for non-tuberculous mycobacterial lung infections

spinceutica.com →
Grants
$1.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Reversing Isoniazid Resistance By Isotopic Substitution$586,360
Federal grantDepartment of Health and Human Services · Phase II · Reversing Isoniazid Resistance By Isotopic Substitution$601,735
Federal grantDepartment of Health and Human Services · Phase I · Overcoming Isoniazid Resistance in Tuberculosis with New Chemical Entitites$187,500
Federal grantDepartment of Health and Human Services · Phase I · Rifampin potentiation in NTM$205,299
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2696IGE THERAPEUTICS, INC.——
2697SUDHIN BIOPHARMA COMPANY——
2698MC1R VENTURES LLC——
2699SpinCeutica, Inc.——
2700VOVA IDA THERAPEUTICS INC——
2701ZVELT THERAPEUTICS INC.——
2702DUB THERAPEUTICS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.